Drug intelligence / Profile preview

PSTC1201

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

PSTC1201 is a small molecule drug developed for the treatment of endocrinology and metabolic diseases. It was initially developed by Eli Lilly and has also been associated with Piramal Enterprises. The drug has been studied in clinical trials, including a randomized, double-blind, placebo-controlled Phase 1 study to determine its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy overweight or obese subjects (study P1201-07). The precise mechanism of action and molecular target have not been disclosed in public sources as of June 2025[4].

Beyond the preview

Go deeper on PSTC1201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSTC1201.

Explore the full profile